CALL/VERTEX PHARMACEUTICALS/600/0.1/17.01.25 | Real-time BOERSE MUENCHEN 01:57:03 29/05/2024 pm IST | ||
| 0.468 EUR | -8.95% |
|
| Current month | +144.76% | ||
| 1 month | +123.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 29/24/29 | 0.468 | -8.95% |
| 28/24/28 | 0.514 | -1.72% |
| 27/24/27 | 0.523 | +8.51% |
| 24/24/24 | 0.482 | +6.40% |
| 23/24/23 | 0.453 | +15.56% |
Real-time BOERSE MUENCHEN
Last update May 29, 2024 at 01:57 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GP93AG |
| ISIN | DE000GP93AG2 |
| Date issued | 17/07/2023 |
| Strike | 600 $ |
| Maturity | 17/01/2025 (234 Days) |
| Parity | 10 : 1 |
| Emission price | 0.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.3 € |
|---|---|
| Lowest since issue | 0.2 € |
| Spread | 0.2 € |
| Spread % | 30.30% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
446.9
USD
Average target price
462.8
USD
Spread / Average Target
+3.57%
- Stock Market
- Warrants
- Warrant
